Diligence memo · auto-generated · as of July 2, 2026
Merus N.V.
Merus N.V. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Merus N.V. operates in Biotechnology, based in 3584 CM UTRECHT.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Merus N.V. has raised $151M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $80M on 2017-01-23.
Most recent recorded round closed around 2018-12-20.
Valuation (modeled)modeled
Provath models Merus N.V. at approximately $614M (range $46M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.30× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 7.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Biotechnology peers (4293 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.